[go: up one dir, main page]

WO2009137572A3 - Inhibition des peptides de la gliadine - Google Patents

Inhibition des peptides de la gliadine Download PDF

Info

Publication number
WO2009137572A3
WO2009137572A3 PCT/US2009/042973 US2009042973W WO2009137572A3 WO 2009137572 A3 WO2009137572 A3 WO 2009137572A3 US 2009042973 W US2009042973 W US 2009042973W WO 2009137572 A3 WO2009137572 A3 WO 2009137572A3
Authority
WO
WIPO (PCT)
Prior art keywords
biological
inhibition
diseases
barrier permeability
peptide translocation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/042973
Other languages
English (en)
Other versions
WO2009137572A2 (fr
Inventor
Sefik Alkan
Amir Tamiz
Kelly Marie Kitchens
Malarvizhi Durai
Neil Poloso
Rosa A. Carrasco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
9 Meters Biopharma Inc
Original Assignee
Alba Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alba Therapeutics Corp filed Critical Alba Therapeutics Corp
Priority to US12/991,658 priority Critical patent/US8957032B2/en
Publication of WO2009137572A2 publication Critical patent/WO2009137572A2/fr
Publication of WO2009137572A3 publication Critical patent/WO2009137572A3/fr
Anticipated expiration legal-status Critical
Priority to US14/592,623 priority patent/US20150203537A1/en
Priority to US15/160,259 priority patent/US20170096451A1/en
Priority to US15/860,118 priority patent/US10526372B2/en
Priority to US16/692,640 priority patent/US11149063B2/en
Priority to US17/483,934 priority patent/US20220009965A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne de nouveaux composés et méthodes d’inhibition de la perméabilité des barrières biologiques et d’inhibition de la translocation des peptides à travers les barrières biologiques. L’invention concerne des dosages permettant de déterminer des modulateurs de perméabilité des barrières biologiques et de translocation des peptides à travers les barrières biologiques. L’invention concerne des méthodes de traitement des maladies associées avec une perméabilité aberrante des barrières biologiques et une translocation aberrante des peptides à travers les barrières biologiques. Parmi ces maladies figurent la maladie cœliaque, l’entérocolite nécrosante, le diabète, le cancer, les maladies inflammatoires chroniques intestinales, l’asthme, la broncho-pneumopathie chronique obstructive, les réponses immunitaires excessives ou indésirables, la sensibilité au gluten, l’allergie au gluten, l’allergie alimentaire, la polyarthrite rhumatoïde, la sclérose en plaques, le diabète de type 1 ou diabète attribuable à un phénomène auto-immunitaire, le lupus érythémateux disséminé, le psoriasis, la sclérodermie et les maladies de la thyroïde auto-immunes.
PCT/US2009/042973 2008-05-06 2009-05-06 Inhibition des peptides de la gliadine Ceased WO2009137572A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US12/991,658 US8957032B2 (en) 2008-05-06 2009-05-06 Inhibition of gliadin peptides
US14/592,623 US20150203537A1 (en) 2008-05-06 2015-01-08 Inhibition of gliadin peptides
US15/160,259 US20170096451A1 (en) 2008-05-06 2016-05-20 Inhibition of gliadin peptides
US15/860,118 US10526372B2 (en) 2008-05-06 2018-01-02 Inhibition of gliadin peptides
US16/692,640 US11149063B2 (en) 2008-05-06 2019-11-22 Peptide inhibitors of tight junction permeability
US17/483,934 US20220009965A1 (en) 2008-05-06 2021-09-24 Peptide inhibitors of tight junction permeability

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5091508P 2008-05-06 2008-05-06
US61/050,915 2008-05-06

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/991,658 A-371-Of-International US8957032B2 (en) 2008-05-06 2009-05-06 Inhibition of gliadin peptides
US14/592,623 Continuation US20150203537A1 (en) 2008-05-06 2015-01-08 Inhibition of gliadin peptides

Publications (2)

Publication Number Publication Date
WO2009137572A2 WO2009137572A2 (fr) 2009-11-12
WO2009137572A3 true WO2009137572A3 (fr) 2010-03-04

Family

ID=41265370

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/042973 Ceased WO2009137572A2 (fr) 2008-05-06 2009-05-06 Inhibition des peptides de la gliadine

Country Status (2)

Country Link
US (6) US8957032B2 (fr)
WO (1) WO2009137572A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011600B2 (en) 2003-02-28 2006-03-14 Fallbrook Technologies Inc. Continuously variable transmission
WO2007061993A2 (fr) 2005-11-22 2007-05-31 Fallbrook Technologies Inc Transmission a variation continue
CN102226460A (zh) 2005-12-09 2011-10-26 瀑溪技术公司 无级变速器
EP1811202A1 (fr) 2005-12-30 2007-07-25 Fallbrook Technologies, Inc. Transmission à variation continue
WO2008052185A2 (fr) * 2006-10-26 2008-05-02 Alba Therapeutics Corp Matériaux et procédés pour le traitement de la maladie cœliaque
WO2008095116A2 (fr) 2007-02-01 2008-08-07 Fallbrook Technologies, Inc. Système et procédés pour la commande d'une transmission et/ou d'un premier moteur d'entraînement
US20100093479A1 (en) 2007-02-12 2010-04-15 Fallbrook Technologies Inc. Continuously variable transmissions and methods therefor
WO2009065055A2 (fr) 2007-11-16 2009-05-22 Fallbrook Technologies Inc. Unité de commande pour transmission variable
PL2234869T3 (pl) 2007-12-21 2012-12-31 Fallbrook Tech Inc Przekładnie automatyczne i sposoby dla przekładni automatycznych
US8957032B2 (en) 2008-05-06 2015-02-17 Alba Therapeutics Corporation Inhibition of gliadin peptides
US8535199B2 (en) 2008-06-06 2013-09-17 Fallbrook Intellectual Property Company Llc Infinitely variable transmissions, continuously variable transmissions, methods, assemblies, subassemblies, and components therefor
US8469856B2 (en) 2008-08-26 2013-06-25 Fallbrook Intellectual Property Company Llc Continuously variable transmission
US8167759B2 (en) 2008-10-14 2012-05-01 Fallbrook Technologies Inc. Continuously variable transmission
EP4151883A1 (fr) 2009-04-16 2023-03-22 Fallbrook Intellectual Property Company LLC Transmission à variation continue
WO2013112408A1 (fr) 2012-01-23 2013-08-01 Fallbrook Intellectual Property Company Llc Transmissions infiniment variables, procédés de transmissions variables en continu, ensembles, sous-ensembles, et composants à cet effet
WO2014044281A1 (fr) * 2012-09-19 2014-03-27 Rigshospitalet Inhibition d'un peptide de 33-mer dérivé de la gliadine pour le traitement du diabète
KR102230514B1 (ko) * 2013-03-07 2021-03-19 바마르사 리서치 엘엘씨 글리아딘 펩타이드를 사용한 암 치료용 키트 및 방법
EP2986494A1 (fr) 2013-04-19 2016-02-24 Fallbrook Intellectual Property Company LLC Transmission à variation continue
US10047861B2 (en) 2016-01-15 2018-08-14 Fallbrook Intellectual Property Company Llc Systems and methods for controlling rollback in continuously variable transmissions
TW201825805A (zh) 2016-03-18 2018-07-16 福柏克智慧財產有限責任公司 用於無級變速器之定子、定子組件及用於控制無級變速器之方法
US10246731B2 (en) * 2016-03-29 2019-04-02 Oneighty°C Technologies Corporation Method for rapidly determining effective sterilization , deimmunization, and/or disinfection
US10023266B2 (en) 2016-05-11 2018-07-17 Fallbrook Intellectual Property Company Llc Systems and methods for automatic configuration and automatic calibration of continuously variable transmissions and bicycles having continuously variable transmissions
CA3052975A1 (fr) * 2017-02-10 2018-08-16 Innovate Biopharmaceuticals, Inc. Compositions et methodes destinees au traitement d'une maladie associee a la permeabilite de l'epithelium intestinal
WO2019165346A1 (fr) * 2018-02-23 2019-08-29 Innovate Biopharmaceuticals, Inc. Composés et méthodes de traitement de la perméabilité des jonctions serrées
US20210361734A1 (en) 2018-03-19 2021-11-25 9 Meters Biopharma, Inc. Compositions and methods for potentiating immune checkpoint inhibitor therapy
US20210069286A1 (en) * 2018-04-09 2021-03-11 9 Meters Biopharma, Inc. Compositions and methods for treating or preventing hyperglycemia, insulin resistance, and associated organ damage
KR101979286B1 (ko) 2018-05-17 2019-05-15 경북대학교병원 부분 경화된 콘택트렌즈형 양막 드레싱 및 이의 제조방법
US11215268B2 (en) 2018-11-06 2022-01-04 Fallbrook Intellectual Property Company Llc Continuously variable transmissions, synchronous shifting, twin countershafts and methods for control of same
US10987315B1 (en) * 2018-12-04 2021-04-27 University Of South Florida Antithrombotic nanoparticles and methods for treating necrotizing enterocolitis
US11174922B2 (en) 2019-02-26 2021-11-16 Fallbrook Intellectual Property Company Llc Reversible variable drives and systems and methods for control in forward and reverse directions
CN115916235A (zh) * 2020-04-15 2023-04-04 九米特生物制药有限公司 包含d-氨基酸的拉瑞唑来衍生物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070196501A1 (en) * 2006-02-09 2007-08-23 Alba Therapeutics Corp. Formulations for a tight junction effector
US20080103100A1 (en) * 2006-10-26 2008-05-01 Alessio Fasano Materials and methods for the treatment of celiac disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458925B1 (en) 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
AU2001249067A1 (en) 2000-05-19 2001-12-03 University Of Maryland, Baltimore Method of use of peptide antagonists of zonulin to prevent or delay the onset ofdiabetes
TW200716159A (en) * 2005-06-09 2007-05-01 Univ Maryland Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells
BRPI0715084A2 (pt) * 2006-08-02 2013-03-12 Sigma Tau Ind Farmaceuthiche Riunite S P A derivados de 4-trimetilamânio-3-aminobutirato e 4-trimetilfosfânico-3-aminobutirato como inibidores de cpt
WO2008043107A2 (fr) 2006-10-06 2008-04-10 Alba Therapeutics Corporation Utilisation d'antagonistes des jonctions occlusives pour traiter les affections abdominales inflammatoires
KR101314254B1 (ko) * 2007-02-16 2013-10-02 삼성전자주식회사 Ｏｆｄｍ 송수신 시스템 및 그 방법
WO2008150981A2 (fr) 2007-05-30 2008-12-11 Alba Therapeutics Corporation Nouveaux peptides courts inhibant l'ouverture de jonctions serrées mammaliennes
US20110201543A1 (en) 2007-06-29 2011-08-18 Blake Paterson Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress
US8785374B2 (en) 2007-10-19 2014-07-22 Alba Therapeutics Corporation Inhibitors of mammalian tight junction opening
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
EP2062909A1 (fr) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Production de peptides et procédé de purification
US8957032B2 (en) 2008-05-06 2015-02-17 Alba Therapeutics Corporation Inhibition of gliadin peptides
EP3591179A1 (fr) 2018-07-03 2020-01-08 Siemens Aktiengesellschaft Conduit de dérivation de vapeur

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070196501A1 (en) * 2006-02-09 2007-08-23 Alba Therapeutics Corp. Formulations for a tight junction effector
US20080103100A1 (en) * 2006-10-26 2008-05-01 Alessio Fasano Materials and methods for the treatment of celiac disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARRIETA ET AL.: "Alterations in Intestinal Permeability.", GUT, vol. 55, no. 10, October 2006 (2006-10-01), pages 1512 - 1520 *

Also Published As

Publication number Publication date
US20170096451A1 (en) 2017-04-06
US10526372B2 (en) 2020-01-07
US8957032B2 (en) 2015-02-17
US20180134750A1 (en) 2018-05-17
US20110275562A1 (en) 2011-11-10
US20200231626A1 (en) 2020-07-23
US20150203537A1 (en) 2015-07-23
US20220009965A1 (en) 2022-01-13
WO2009137572A2 (fr) 2009-11-12
US11149063B2 (en) 2021-10-19

Similar Documents

Publication Publication Date Title
WO2009137572A3 (fr) Inhibition des peptides de la gliadine
WO2006091734A3 (fr) Compositions et procedes de classification d'echantillons biologiques
Armengaud et al. Exoproteomics: exploring the world around biological systems
HK1201565A1 (en) Quantification of adaptive immune cell genomes in a complex mixture of cells
WO2006084264A3 (fr) Variants d'anticorps et utilisations
WO2014013075A3 (fr) Anticorps dirigés contre des cibles hautement conservées
EP2949667A3 (fr) Protéines recombinantes de capture de surface cellulaire
IN2014CN00807A (fr)
MX2012009175A (es) Metodos para identificar y aislar celulas que expresan un polipeptido.
EP4434543A3 (fr) Variantes de la region fc d'igg1 humane et leurs utilisations
MX2010001616A (es) Fragmentos de clivaje de inmunoglobulina como indicadores de enfermedad y composiciones para detectarlos y unirlos.
WO2013138044A8 (fr) Procédés et matériaux pour la détection non invasive d'une néoplasie colorectale associée à une affection abdominale inflammatoire
WO2005016127A3 (fr) Reactifs peptidiques specifiques du prion
WO2004093908A3 (fr) Compositions et techniques destinees a la therapie d'une maladie intestinale inflammatoire
WO2016205828A3 (fr) Rôle de la citrullination dans le diagnostic de maladies
EP1972639A3 (fr) Réactifs pour la détection de la phosphorylation de protéines dans des voies signalant un carcinome
Cassiano et al. Heteronemin, a marine sponge terpenoid, targets TDP-43, a key factor in several neurodegenerative disorders
WO2007087263A3 (fr) Citrate, zinc et zip1 humain destines au criblage d’un cancer de la prostate
WO2006091421A3 (fr) Peptides pour la detection d'un anticorps dirige contre ehrlichia ewingii
Ang et al. Murine fecal proteomics: a model system for the detection of potential biomarkers for colorectal cancer
WO2008109533A3 (fr) Anticorps se liant à des protéines multiples de la famille irta et leurs utilisations
WO2011137389A3 (fr) Compositions et procédés destinés à détecter et/ou à mesurer de manière fiable la quantité d'une protéine modifiée cible dans un échantillon
WO2007067983A3 (fr) Anticorps specifique de la sulfotyrosine et utilisation a cet effet
Hanna et al. Proteomic analysis of human natural killer cells: insights on new potential NK immune functions
WO2017156038A3 (fr) Étalons internes pour dosages immunologiques et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09743558

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12991658

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 09743558

Country of ref document: EP

Kind code of ref document: A2